Studies in cancers other than PC (i.e. ovarian and prostate) have shown that BRCA1 and BRCA2 are not the only genes whose alteration is essential in this context: indeed, the wider concept of HR deficiency, including other genes such as ATM or PALB2, is implicated in the exploitation of synthetic lethality [15–20]. This evidence concerns the gene BRCA1 and cancer.